Oppenheimer assumed coverage of MediWound (MDWD) with an Outperform rating with a price target of $34, down from $36. The firm notes the company’s Q1 update highlighted progress across its clinical and commercial programs. Global EscharEx Phase 3 VALUE trial recruitment is underway, with most U.S. sites open, and interim data expected mid-2026. Given design similarities to Phase 2, Oppenheimer views Phase 3 as significantly derisked. MediWound’s strategic collaborations and overall key opinion leader enthusiasm further validate EscharEx’s clinical/commercial potential, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDWD:
- MediWound’s Earnings Call: Mixed Outlook with Promising Growth
- MediWound price target raised to $31 from $25 at H.C. Wainwright
- MediWound’s Q1 2025: Strategic Progress Amid Financial Challenges
- Mediwound’s Strategic Growth and Positive Outlook Drive Buy Rating
- MediWound Announces Q1 2025 Results and Updates on Key Trials